Ubiquitin-centered post-translational modification crosstalk orchestrates tumor immunity and immunotherapy response

Area of Science:

• Immunology
• Oncology
• Biochemistry

Background:

• Cancer immunotherapy has advanced but faces challenges like limited response rates and resistance.
• Ubiquitination is a crucial post-translational modification (PTM) regulating tumor immunity, influencing recognition and evasion.
• Ubiquitination interacts with other PTMs, forming a complex network that impacts the immune microenvironment and therapeutic outcomes.

Purpose of the Study:

• To systematically review how ubiquitination-related enzymes modulate the tumor immune microenvironment and immune evasion.
• To highlight the crosstalk between ubiquitination and other PTMs in governing immune regulators.
• To discuss the translational potential of targeting the ubiquitin system for cancer immunotherapy.

Main Methods:

• Systematic review of literature on ubiquitination in tumor immunity.
• Analysis of molecular mechanisms of ubiquitination-related enzymes.
• Discussion of PTM crosstalk and therapeutic targeting strategies.

Main Results:

• Ubiquitination, through ubiquitin ligases and deubiquitinases, fine-tunes immune responses and tumor recognition.
• Ubiquitination collaborates with other PTMs (phosphorylation, acetylation, etc.) to regulate immune signaling.
• Targeting the ubiquitin system presents opportunities and challenges for developing novel immunotherapies.

Conclusions:

• Understanding the integrated PTM network, particularly ubiquitination, is key to deciphering tumor immunity.
• Targeting ubiquitination and its crosstalk with other PTMs offers promising avenues for precision cancer immunotherapy.
• Further research into selective ubiquitin modulators and combination therapies is warranted.